Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid

Neuroscience

Volumn 82, Issue 1, 1997, Pages 117-127

  Araujo, D M ^a   Hilt, D C ^a  

^a AMGEN INC   (United States)

Author keywords

GABA neuroprotection; Huntington's disease; Neurodegenaration; Tiagabine excitotoxity

Indexed keywords

3 NITROPROPIONIC ACID; 4 AMINOBUTYRIC ACID; CHOLINE; CHOLINE ACETYLTRANSFERASE; DOPAMINE RECEPTOR; DYNORPHIN A; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; METENKEPHALIN; NEUROTOXIN; NEUROTRANSMITTER; SUBSTANCE P; TIAGABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEGENERATION; CONTROLLED STUDY; FEMALE; LOCOMOTION; NEUROCHEMISTRY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AUTORADIOGRAPHY; CHOLINE O-ACETYLTRANSFERASE; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INJECTIONS, INTRAVENTRICULAR; MITOCHONDRIA; MOTOR ACTIVITY; NEOSTRIATUM; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NIPECOTIC ACIDS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA; SUBSTANTIA NIGRA;

EID: 0030929943     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00266-2     Document Type: Article

References (61)

1. Albin R. L., Greenamyre J. T. Alternative excitotoxic hypotheses. Neurology. 42:1992;733-738.
2. Alston T. A., Mela L., Bright H. J. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc. natn. Acad. Sci. U.S.A. 74:1977;3767-3771.
3. Anderson K. D., Panayotatos N., Corcoran T. L., Lindsay R. M., Wiegand S. J. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington's disease. Proc. natn. Acad. Sci. U.S.A. 93:1996;7346-7351.
4. Araujo D. M., Hilt D. C. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease. Neuroscience. 81:1997;1099-1110.
5. Araujo D. M., Lapchak P. A., Meaney M. J., Collier B., Quirion R. Effects of aging on nicotinic and muscarinic autoreceptor function in the rat brain: relationship to presynaptic cholinergic markers and binding sites. J. Neurosci. 10:1990;3069-3078.
6. Araujo D. M., Lapchak P. A., Hefti F. Effects of chronic basic fibroblast growth factor administration to rats with partial fimbrial transactions on presynaptic cholinergic parameters and muscarinic receptors in the hippocampus: comparison with nerve growth factor. J. Neurochem. 61:1993;899-910.
7. Beal M. F. Neurochemistry and toxin models in Huntington's disease. Curr. Opin. Neurol. 7:1994;542-547.
8. Beal M. F., Brouillet E., Jenkins B. G., Ferrante R. J., Kowall N. W., Miller J. M., Storey E., Srivastava R., Rosen B. R., Hyman B. T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:1993;4181-4192.
9. Beal M. T., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J., Martin J. B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
10. Borlongan C. V., Koutouzis T. K., Freeman T. B., Cahill D. W., Sanberg P. R. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Res. 697:1995;254-257.
11. Borlongan C. V., Koutouzis T. K., Randall T. S., Freeman T. B., Cahill D. W., Sanberg P. R. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res. Bull. 36:1995;549-556.
12. Bossi S. R., Simpson J. R., Isacson O. Age dependence of striatal neuronal death caused by mitochondrial dysfunction. NeuroReport. 4:1993;73-76.
13. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Analyt. Biochem. 72:1976;248-253.
14. Brouillet E., Hantraye P., Ferrante R. J., Dolan R., Willig A. L., Kowall N. W., Beal M. F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. natn. Acad. Sci. U.S.A. 92:1995;7105-7109.
15. Brouillet E., Jenkins B. G., Hyman B. T., Ferrante R. L, Kowall N. W., Srivastava R., Roy D. S., Rosen B. R., Beal M. F. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60:1993;356-359.
16. Coles C. J., Edmondson D. E., Singer T. P. Inactivation of succinate dehydrogenase by 3-nitropropionate. J. biol. Chem. 254:1979;5161-5167.
17. Dawbarn D., De Quidt M. E., Emson P. C. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res. 340:1985;251-260.
18. Dawson R. Jr., Beal M. F., Bondy S. C., DiMonte D. A., Isom G. E. Excitotoxins, aging, and environmental neurotoxins: implications for understanding human neurodegenerative diseases. Toxic. appl. Pharmac. 134:1995;1-17.
19. Emerich D. F., Hammang J. P., Baetge E. E., Winn S. R. Implantation of polymer-encapsulated human nerve growth factor-secreting fibroblasts attenuates the behavioral and neuropathological consequences of quinolinic acid injections into rodent striatum. Expl Neurol. 130:1994;141-150.
20. Emerich D. F., Lindner M. D., Winn S. R., Chen E. Y., Frydel B. R., Kordower J. H. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. 16:1996;5168-5181.
21. Ferrante R. J., Kowall N. W., Richardson E. P. Jr. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 11:1991;3877-3887.
22. Ferrante R. L., Kowall N. W., Richardson E. P. Jr., Bird E. D., Martin J. B. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. Neurosci. Lett. 71:1986;283-288.
23. 3H]forskolin binding. Expl Neurol. 110:1990;219-227.
24. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24:1975;407-409.
25. Frim D. M., Short M. P., Rosenberg W. S., Simpson J., Breakefield X. O., Isacson O. Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. J. Neurosurg. 78:1993;267-273.
26. Frim D. M., Simpson J., Uhler T. A., Short M. P., Bossi S. R., Breakefield X. O., Isacson O. Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J. Neurosci. Res. 35:1993;452-458.
27. Frim D. M., Uhler T. A., Short M. P., Ezzedine Z. R., Klagsbrun M., Breakefield X. O., Isacson O. Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. NeuroReport. 4:1993;367-370.
28. Fu Y., He F., Zhang S., Huang J., Zhang J., Jiao X. 3-Nitropropionic acid produces indirect excitotoxic damage to rat striatum. Neurotox. Terat. 17:1995;333-339.
29. Gerfen C. R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. A. Rev. Neurosci. 15:1992;285-320.
30. Gould D. H., Gustine D. L. Basal ganglia degeneration, myelin alterations, and enzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid. Neuropath. appl. Neurobiol. 8:1982;377-393.
31. Gu M., Gash M. T., Mann V. M., Javoy-Agid E., Cooper J. M., Schapira A. H. V. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39:1996;385-389.
32. Hamilton B. F., Gould D. H. Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage. Acta neuropath., Berlin. 72:1987;286-297.
33. Hassel B., Sonnewald U. Selective inhibition of the tricarboxylic acid cycle of GABAergic neurons with 3-nitropropionic acid in vivo. J. Neurochem. 65:1995;1184-1191.
34. Heimer L., Zahm D. S. and Alheid G. F. (1995) Basal Ganglia. In The Rat Nervous System (ed Paxinos G.), pp. 579-628. Academic Press Inc., San Diego.
35. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983.
36. 2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse. 2:1988;546-557.
37. Kordower J. H., Charles V., Bayer R., Bartus R. T., Putney S., Walus L. R., Friden P. M. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington's disease. Proc. natn. Acad. Sci. U.S.A. 91:1994;9077-9080.
38. Koutouzis T. K., Borlongan C. V., Freeman T. B., Cahill D. W., Sanberg P. R. Intrastriatal 3-nitropropionic acid: a behavioral assessment. NeuroReport. 5:1994;2241-2245.
39. Koutouzis T. K., Borlongan C. V., Scorcia T., Creese I., Cahill D. W., Freeman T. B., Sanberg P. R. Systemic 3-nitropropionic acid: long-term effects on locomotor behavior. Brain Res. 646:1994;242-246.
40. Lapchak P. A. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev. Neurosci. 7:1996;165-176.
41. Lapchak P. A., Gash D. M., Collins F., Hilt D., Miller P. J., Araujo D. M. Pharmacological activities of glial cell line-derived neurotropic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Expl Neurol. 145:1997;309-321.
42. Lapchak P. A., Miller P. L., Collins F. and Jiao S. (1996) Glial cell line-derived neurotrophic factor attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience, (in press).
43. Lapchak P. A., Miller P. J. and Jiao S. (1997) Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats. Neuroscience 76, (in press).
44. Lapchak P. A., Miller P. J., Jiao S., Araujo D. M., Hilt D., Collins F. Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration. 5:1996;197-205.
45. Levivier M., Holemans S., Togasaki D. M., Maloteaux J. M., Brotchi J., Przedborski S. Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. Neurol. Res. 16:1994;194-200.
46. Ludolph A. C., He F., Spencer P. S., Hammerstad J., Sabri M. 3-Nitropropionic acid - erogenous animal neurotoxin and possible human striatal toxin. Can. J. neurol. Sci. 18:1991;492-498.
47. Martin D., Miller G., Rosendahl M., Russell D. A. Potent inhibitory effects of GDNF against kainic acid mediated seizures in rats. Brain Res. 683:1995;172-178.
48. Martin J. B., Beal M. F. Huntington's disease and neurotoxins. Ann. N. Y. Acad. Sci. 648:1992;169-175.
49. Palfi S., Ferrante R. J., Brouillet E., Beal M. F., Dolan R., Guyot M. C., Peschanski M., Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci. 16:1996;3019-3025.
50. Paxinos G. and Watson C. (1992) The Rat Brain in Stereotaxic Coordinates (2nd edn). Academic, New York.
51. Pei G., Ebendal T. Specific lesions in the extrapyramidal system of the rat brain induced by 3-nitropropionic acid (3-NPA). Expl Neurol. 132:1995;105-115.
52. Perez-Navarro E., Arenas E., Reiriz J., Calvo N., Alberch J. Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage. Neuroscience. 75:1996;345-352.
53. Reiner A., Albin R. L., Anderson K. D., D'Amato C. J., Penney J. B., Young A. B. Differential loss of striatal projection neurons in Huntington disease. Proc. natn. Acad. Sci. U.S.A. 85:1988;5733-5737.
54. Schulz J. B., Beal M. F. Mitochondrial dysfunction in movement disorders. Curr. Opin. Neurol. 7:1994;333-339.
55. Schulz J. B., Matthews R. T., Henshaw D. R., Beal M. F. Neuroprotective strategies for the treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience. 71:1996;1043-1048.
56. Schulz J. B., Matthews R. T., Jenkins B. G., Ferrante R. J., Siwek D., Henshaw D. R., Cipolloni P. B., Mecocci P., Kowall N. W., Rosen B. R., Beal M. F. Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J. Neurosci. 15:1995;8419-8429.
57. Sharp A. H., Ross C. A. Neurobiology of Huntington's disease. Neurobiol. Disease. 3:1996;3-15.
58. Simpson J. R., Isacson O. Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Expl Neurol. 121:1993;57-64.
59. 3H]tiagabine (NNC 05-328) to the GABA uptake carrier. Brain Res. 647:1994;231-234.
60. Wullner U., Young A. B., Penney J. B., Beal M. F. 3-Nitropropionic acid toxicity in the striatum. J. Neurochem. 63:1994;1772-1781.
61. Zeevalk G. D., Derr-Yellin D., Nicklas W. J. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J. Pharmac. exp. Ther. 275:1995;1124-1130.